Transition Therapeutics, Inc.
(Toronto Stock Exchange : TTHI)

( )
TTHI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
TMOThermo Fisher Scientific, Inc. 0.64%470.771.0%$739.18m
ABTAbbott Laboratories 0.29%118.850.8%$608.52m
DHRDanaher Corp. 0.97%256.960.7%$569.61m
MDTMedtronic Plc 0.18%127.230.6%$561.46m
ISRGIntuitive Surgical, Inc. 0.48%842.462.3%$487.78m
BSXBoston Scientific Corp. -0.05%43.071.0%$351.26m
ALGNAlign Technology, Inc. 2.72%584.726.3%$328.32m
BDXBecton, Dickinson & Co. -3.46%241.141.0%$319.10m
NVCRNovoCure Ltd. -4.02%193.656.8%$314.36m
SYKStryker Corp. 0.44%254.191.3%$270.73m
EWEdwards Lifesciences Corp. -0.07%91.710.4%$267.36m
DXCMDexCom, Inc. -2.35%357.347.8%$253.43m
AAgilent Technologies, Inc. -0.65%132.511.6%$207.05m
BAXBaxter International, Inc. 0.89%87.471.8%$187.10m
NVSTEnvista Holdings Corp. 4.67%44.840.0%$183.95m

Company Profile

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 for the treatment of Alzheimer's disease and TT223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine.